It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or
consider using other browsers such as Chrome, Firefox or Safari.
No confirmed PML cases were reported with ofatumumab in any of the clinical studies with relapsing MS or in the post-market setting through 25 Sep 2023.
PML, progressive multifocal leukoencephalopathy
References
1. Data on file. Novartis Pharma AG.
For US Healthcare Professionals only
This website is intended to provide information for HCPs in the US only.
Please confirm that you are a HCP from the US
For HCPs outside the US: Thank you for your interest in the safety website for ofatumumab in relapsing multiple sclerosis. This website is intended for HCPs in the US only.
For Non-HCPs / Patients: This ofatumumab safety website is currently available for US HCPs only.